6 Best ASX Healthcare Stocks to Buy in 2026

Why Trade ASX Stocks with Mitrade?

Try Free Demo Account

The healthcare sector has long been regarded as one of the bedrocks of the global economy. Regardless of economic cycles, people require medical treatment, prescription medicines, diagnostic services and healthcare technologies daily. This consistent demand has helped many healthcare companies deliver steady long-term growth.

The same applies to healthcare companies in Australia, which is home to some of the world's notable providers. Some of these companies have unique ASX healthcare stocks for investors, making it easy to diversify beyond banks, mining companies and technology stocks. But what are the ASX healthcare stocks to watch in 2026 and how can Australian investors gain exposure to these companies? Let’s find out.

ASX healthcare stocks belong to publicly listed companies on the Australian Securities Exchange (ASX) that operate within the healthcare industry.

Unlike the general belief that healthcare investing is solely for pharmaceutical companies, Australia's healthcare industry includes businesses across biotechnology, medical devices, diagnostic imaging, pathology services, digital healthcare, among others.

Some healthcare companies focus on developing new medicines and treatments through years of clinical research, while others manufacture life-saving medical devices or provide essential healthcare services used every day by hospitals and clinicians.

For investors, healthcare also provides exposure to an industry driven by long-term demographic and technological trends. 

The healthcare sector is arguably the most resilient due to its crucial importance to everyone worldwide. But here are more reasons to consider an ASX healthcare stock: 

1. A Growing and Ageing Population

With 1 in every 6 Australians aged 65 and above, the country’s population continues to age, and similar trends are occurring across much of the developed world. Older populations generally require more medical care, pharmaceuticals, diagnostic services and specialised treatments, creating long-term demand for healthcare providers and medical technology companies.

2, Innovation Is Creating New Opportunities

Healthcare is no longer primarily about traditional pharmaceuticals. Today's healthcare companies are increasingly developing technologies like artificial intelligence (AI), robotic surgery, cloud-based medical imaging, precision diagnostics and digital monitoring systems.

Companies that successfully commercialise these innovations can achieve significant long-term growth while expanding into international markets.

3. Global Revenue Streams

Many of the best ASX healthcare stocks earn a substantial portion of their revenue outside Australia. This international exposure reduces reliance on domestic economic conditions while allowing companies to benefit from healthcare spending across larger global markets.

SELL BUY

Sector: Biotechnology
Market Capitalisation: Large Cap

CSL is widely regarded as Australia's flagship healthcare company and has been one of the strongest long-term performers on the ASX. Founded in 1916, the company has grown into a global biotechnology leader specialising in plasma therapies, vaccines and treatments for rare and serious diseases.

Today, CSL operates in more than 100 countries and generates the vast majority of its revenue from international markets, particularly the United States and Europe. 

Its plasma collection business, CSL Behring, is one of the largest in the world, supplying life-saving therapies used to treat immune deficiencies, bleeding disorders and neurological conditions. Through its Seqirus division, the company is also one of the world's largest influenza vaccine manufacturers.

One reason CSL continues to feature among the best ASX healthcare stocks is its ability to combine consistent revenue growth with substantial investment in research and development. 

Pros

• Global biotechnology leader.

• Diversified healthcare portfolio.

• Strong international revenue base.

• Consistent investment in innovation.

Cons

• High research and development costs.

• Currency fluctuations due to global operations.

Sector: Healthcare Technology
Market Capitalisation: Large Cap

Pro Medicus is one of Australia's most successful healthcare technology companies. Its flagship Visage imaging platform enables hospitals and radiology providers to process and access complex medical images quickly, improving workflow efficiency. As healthcare providers continue digitising operations, demand for advanced imaging software has increased significantly.

Financially, Pro Medicus has delivered exceptional revenue growth, strong operating margins and impressive returns on capital over many years. Investors have rewarded this performance, making it one of the standout performers among ASX healthcare stocks.

Pros

• Global medical imaging software leader.

• High-margin recurring revenue.

• Strong presence in the US healthcare market.

• Long-term digital healthcare trends.

Cons

• Premium valuation.

• Increasing competition in healthcare software.

SELL BUY

Sector: Medical Devices
Market Capitalisation: Large Cap

Cochlear has spent decades establishing itself as the global leader in implantable hearing solutions. The company's cochlear implants help people with severe hearing loss regain their ability to hear, dramatically improving quality of life for hundreds of thousands of patients worldwide. 

It also provides bone conduction hearing solutions and ongoing sound processor upgrades that support recurring revenue throughout the lifetime of its products.

As demand for hearing healthcare grows over time, Cochlear is poised for exponential growth. The company will also continue to benefit from substantial investment in research and development.

Pros 

• Global leader in hearing implant technology.

• Strong competitive advantages.

• High barriers to entry.

• Ageing population supports long-term demand.

Cons

• Product recalls.

• Regulatory approvals.

SELL BUY

Sector: Medical Technology
Market Capitalisation: Large Cap

ResMed is a global leader in sleep and respiratory care, developing medical devices and digital health solutions used to diagnose and treat sleep apnoea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions.

The company's best-known products include continuous positive airway pressure (CPAP) devices, masks and cloud-connected healthcare software that allows clinicians to monitor patient therapy remotely.

Sleep disorders remain significantly underdiagnosed worldwide, creating substantial opportunities for future growth. At the same time, increasing obesity rates and ageing populations are expected to drive further demand for sleep-related healthcare services.

ResMed has also invested heavily in digital health technology, integrating connected devices and cloud-based software into its product ecosystem. These recurring digital services strengthen customer relationships while creating additional revenue streams beyond hardware sales.

Pros

• Global sleep technology leader.

• Expanding digital health platform.

• Large international customer base.

• Recurring revenue opportunities.

Cons

• Competitive medical device market.

• Regulatory compliance requirements.

Sector: Biotechnology & Precision Medicine
Market Capitalisation: Large Cap

Telix Pharmaceuticals has become one of Australia's fastest-growing biotechnology companies.The healthcare provider specialises in radiopharmaceuticals, which are medicines that help with cancer detection and therapy. 

This fast growing field of precision medicine is attracting significant investment worldwide, positioning Telix as an early mover with massive potential.

Besides, Telix has successfully transitioned from a development-stage biotechnology company to a commercial business generating meaningful revenue. This distinguishes it from many early-stage biotech firms that remain dependent on external funding while awaiting regulatory approvals.

The company's pipeline also extends beyond its currently commercialised products, with additional diagnostic and therapeutic candidates progressing through various stages of development. Continued regulatory approvals, successful product launches and international expansion could all support the company’s future growth.

Pros

• Growing precision medicine business.

• Commercialised healthcare products.

• Expanding international opportunities.

• Strong pipeline of future therapies.

Cons

• Regulatory approval delays.

• Competition from other biotechnology companies.

Sector: Infection Prevention Technology
Market Capitalisation: Mid Cap

Nanosonics operates in a specialised healthcare segment called infection prevention.Its flagship product, trophon, is an automated system used by hospitals and healthcare providers to disinfect ultrasound probes quickly and effectively. 

As infection control standards continue to tighten globally, demand for automated disinfection technologies has increased across hospitals, diagnostic centres and outpatient clinics.

Nanosonics also generates recurring revenue through consumables and service contracts, which creates a more predictable revenue stream as the business builds long-term customer relationships.

Although Nanosonics is smaller than competitors such as CSL and Cochlear, its focus on hospital infection prevention positions it within an industry supported by long-term demand and increasing regulatory attention.

Pros

• Leader in infection prevention technology.

• Recurring consumables revenue.

• Global expansion opportunities.

• Growing demand for hospital hygiene solutions.

Cons

• Adoption rates for new products may be slow.

• Competition from larger medical technology providers.

Many people use healthcare stocks interchangeably with biotechnology stocks. However, they represent different parts of the healthcare industry.

Healthcare stocks include companies involved in medical devices, diagnostics, healthcare software, pathology, hearing technology, hospitals and pharmaceutical manufacturing. These businesses often generate recurring revenue from established products and services and may have relatively predictable cash flows.

Biotechnology companies, by contrast, are typically focused on researching and developing new medicines or therapies. Their success often depends on clinical trial outcomes, regulatory approvals and the commercialisation of new products.

As a result, biotechnology stocks can offer significant growth potential but are generally more volatile than the broader healthcare sector.

There are three primary ways available to Australian investors interested in buying healthcare stocks: 

• Buy individual company stocks on the ASX and hold for the future. 

• Invest in exchange-traded funds (ETFs) with a basket of investment options, including ASX healthcare stocks. 

• Trade ASX healthcare stocks through Contracts for Difference (CFDs).

Rather than purchasing physical shares, platforms like Mitrade allow investors to trade ASX healthcare stock CFDs. With CFD trading, you are speculating on the price movements of healthcare companies, so you don’t need to own the underlying shares.

Unlike traditional investing, CFD trading also allows traders to potentially benefit from both rising and falling markets by taking either long or short positions. The flexibility is why many experienced traders choose the trading model. 

The healthcare industry has existed since time immemorial, and as demand continues to grow, it will keep being one of the most resilient and innovative sectors in Australia. As more people age, healthcare spending will likely increase and many ASX healthcare stocks would be well positioned to benefit. 

Companies such as CSL, Pro Medicus, Cochlear, ResMed, Telix Pharmaceuticals and Nanosonics operate in different areas of the healthcare ecosystem, providing investors with exposure to biotechnology, medical devices, healthcare software, precision medicine and infection prevention technology.

Open a Mitrade account today and start investing in Australia’s biggest healthcare firms. 

You might be interested in…